In the developing myocardium, vascular endothelial growth factor (VEGF)-dependent neovascularization occurs by division of existing vessels, a process that persists for several weeks following birth. During this remodeling phase, mRNA expression of 3 integrin in the heart decreases significantly as vessel maturation progresses. However, in male mice lacking 3, coronary capillaries fail to mature and continue to exhibit irregular endothelial thickness, endothelial protrusions into the lumen, and expanded cytoplasmic vacuoles. Surprisingly, this phenotype was not seen in female 3-null mice. Enhanced VEGF signaling contributes to the 3-null phenotype, because these vessels can be normalized by inhibitors of VEGF or Flk-1. Moreover, intravenous injection of VEGF induces a similar
IntroductionIntegrins often cooperate with angiogenic growth factor receptors and are critical components of signaling pathways leading to angiogenesis. 1 Integrins provide physical and chemical links between cells and extracellular matrix, serving as structural organizers, mechanotransducers, and signaling molecules. In this context, integrin-mediated signaling could uniquely affect the structure and function of an individual cell based on its microenvironment (extracellular matrix components, tissue oxygenation, and growth factor concentration) and expression of particular integrin subunits and/or growth factor receptors. Integrin ␣v3 is either absent or expressed at low levels on normal endothelial cells in vivo but is significantly elevated on the angiogenic blood vessels associated with wounds, inflammatory sites, 2 or tumors. 3 Accordingly, integrin ␣v3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels while sparing the quiescent endothelial cells on pre-existing vessels. 3,4 These results support the concept that ␣v3 regulates endothelial-cell survival to support tumor growth and angiogenesis.However, in apparent disagreement with studies using ␣v3 integrin antagonists, mice lacking 3 actually show an enhanced angiogenic response in tumors. 5 Despite this apparent controversy, 3-null mice provide an interesting tool to study the requirement of ␣v3 and ␣IIb3 in various tissues and cell types (reviewed by Hynes and Hodivala-Dilke 6 ). The 3-null mouse was originally described as a model of Glanzmann thrombasthenia, 7 a pathology that is often associated with impaired ␣IIb3 expression or function in platelets. The 3-null mouse shows defects in platelet aggregation and bleeding 7 as well as enhanced vascular endothelial growth factor (VEGF)-induced endothelial-cell migration, proliferation, permeability, and angiogenesis. 5,8 Enhanced tumor growth in 3-null mice has been attributed to increased endothelial-cell expression of the VEGF receptor Flk-1/KDR 9 and decreased macrophage infiltration. 9,10 3-null mice also have enhanced inflammatory 11 and wound healing responses, 12 the latter due to increased fibroblast infiltration and increased TGF-1 expression. 12 Together, these result...